Morphotek(®) Inc.

Jan 24, 2018

Morphotek To Present Poster On CA125 Suppression Of Humoral Immune Responses Of Antibodies At The Upcoming ASCO-SITC Clinical Immuno-oncology Symposium

Jan 10, 2018

Morphotek Announces FDA Acceptance Of Investigational New Drug Application For Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202

Dec 07, 2017

Morphotek To Present Its Proprietary RESPECT(TM) Antibody-Drug Conjugate (ADC) Technology At The Upcoming Antibody Engineering & Therapeutics Conference In San Diego

Dec 04, 2017

Morphotek Announces Initiation Of Phase 1 Study Of Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202 In Solid Tumors With Folate Receptor Alpha Expression

Nov 13, 2017

Morphotek To Present Its Proprietary RESPECT(TM) Antibody Drug Conjugate (ADC) Technology At The Upcoming 9th Annual PEGS Europe In Lisbon

Sep 19, 2017

Morphotek To Present Preclinical Data On Antibody-Drug Conjugate MORAb-202 At The Upcoming 8th Annual World ADC In San Diego

Sep 05, 2017

Morphotek®, Inc. Announces an Agreement with Fujirebio Diagnostics, Inc. to Commercialize the CA125 II Assay as a Companion Diagnostic for Farletuzumab®